Baseline characteristics
| Telaprevir | Boceprevir | |
|---|---|---|
| Patients | 29 (58%) | 21 (42%) |
| Type of patient | ||
| treatment-naive | 5 (17.24%) | 4 (19.05%) |
| recurrent | 4 (13.79%) | 10 (47.62%) |
| non-responder | 20 (68.97%) | 7 (33.33%) |
| Liver fibrosis | ||
| 0–1 | 6 (20.69%) | 1 (4.76%) |
| 2 | 6 (20.69%) | 2 (9.52%) |
| 3–4 | 17 (58.62%) | 19 (90.48%) |